Table 2.
Patient’s demographics according to responder or non-responder.
| Variables | Total patients | Responder | Non-responder | p value |
|---|---|---|---|---|
| N = 45 | N = 23 | N = 22 | ||
|
Age ≤ 69/> 69 years |
24/21 | 13/10 | 11/11 | 0.76 |
|
Gender Male/female |
36/9 | 20/3 | 16/6 | 0.28 |
|
Smoking Yes/no |
41/4 | 20/3 | 21/1 | 0.61 |
|
PS 0–1/2–3 |
29/16 | 15/8 | 14/8 | > 0.99 |
|
Histology AC/non-AC |
22/23 | 10/13 | 12/10 | 0.76 |
|
Distant meta Yes/no |
34/11 | 16/7 | 18/4 | 0.49 |
|
ILD Yes/no |
15/30 | 6/17 | 9/13 | 0.35 |
|
Previous radiation Yes/no |
14/31 | 5/18 | 9/13 | 0.21 |
|
BMI High/low |
20/25 | 14/9 | 6/16 | 0.03 |
|
NLR High/low |
22/23 | 12/11 | 10/12 | 0.76 |
|
CRP ≤ 1.0/> 1.0 |
20/25 | 12/11 | 8/14 | 0.37 |
|
SUVmax High/low |
19/26 | 8/15 | 11/11 | 0.37 |
|
MTV High/low |
10/35 | 3/20 | 7/15 | 0.16 |
|
TLG High/low |
19/26 | 8/15 | 11/11 | 0.37 |
|
PD-L1 ≤ 75/> 75 (%) |
24/21 | 12/11 | 12/10 | > 0.99 |
PS performance status, AC adenocarcinoma, ILD interstitial lung disease, BMI body mass index, NLR neutrophil to lymphocyte ratio, CRP C-reactive protein, TLG total lesion glycolysis, MTV metabolic tumor volume, SUVmax the maximum of standardized uptake value, PD-L1 programmed death ligand-1.
Bold means statistical significance.